Table 1.

Secondary prevention clinical trials in Alzheimer’s disease.

	DIAN-TU	API-ADAD	A4	TOMMORROW	API-APOε4
Target population	Autosomal dominant AD	Autosomal dominant AD	Cognitively normal, beta- amyloid positive	Cognitively normal with genetic risk	Cognitively normal with genetic risk
Specific characteristics	ADAD mutation carriers	PSEN1 E280A mutation carriers	Positive brain amyloid PET	TOMM40 / APOE genotype	Homozygous APOε4 genotype
Estimated enrollment	210	300	1,150	5,800	1,340
Phase	Phase II/III	Phase II	Phase III	Phase III	Phase II/III
Compound	Gantenerumab, Solanezumab	Crenezumab	Solanezumab	Pioglitazone	CAD106, CNP520
Mechanism	Anti-Aβ antibodies	Anti-Aβ antibody	Anti-Aβ antibody	PPAR-γ agonist	Aβ vaccine & BACE inhibitor
Status	Recruiting	Recruiting	Recruiting	Recruiting	Not yet recruiting
Primary outcome	Composite cognitive test score	Composite cognitive test score	Composite cognitive test score	Time to diagnosis of MCI due to AD	Time to diagnosis of MCI due to AD, composite cognitive test score
Study duration	4 years	5 years	3 years	5 years	5 years
Study identifier	NCT01760005	NCT01998841	NCT02008357	NCT01931566	NCT02565511
Reference	Moulder et al., 2013 [23]	Reiman et al., 2011 [24]	Sperling et al., 2014 [25]	Roses et al., 2014 [26]	Reiman et al., 2011 [24]